BridgeBio Pharma Inc - Asset Resilience Ratio
BridgeBio Pharma Inc (BBIO) has an Asset Resilience Ratio of 0.30% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read BridgeBio Pharma Inc (BBIO) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how BridgeBio Pharma Inc's Asset Resilience Ratio has changed over time. See BBIO book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down BridgeBio Pharma Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of BridgeBio Pharma Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $2.99 Million | 0.3% |
| Total Liquid Assets | $2.99 Million | 0.30% |
Asset Resilience Insights
- Limited Liquidity: BridgeBio Pharma Inc maintains only 0.30% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
BridgeBio Pharma Inc Industry Peers by Asset Resilience Ratio
Compare BridgeBio Pharma Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for BridgeBio Pharma Inc (2019–2024)
The table below shows the annual Asset Resilience Ratio data for BridgeBio Pharma Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | $0.00 | $919.34 Million | -- |
| 2023-12-31 | 10.79% | $58.95 Million | $546.38 Million | -4.50pp |
| 2022-12-31 | 15.29% | $95.23 Million | $623.04 Million | -28.44pp |
| 2021-12-31 | 43.73% | $442.89 Million | $1.01 Billion | +8.05pp |
| 2020-12-31 | 35.68% | $251.01 Million | $703.59 Million | +6.83pp |
| 2019-12-31 | 28.85% | $182.22 Million | $631.68 Million | -- |
About BridgeBio Pharma Inc
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM);… Read more